TP53 and neoplasm: 1. TIS can be induced in cancer cells lacking functional p53 and retinoblastoma protein using specific anticancer compounds or radiation.2. TIS may lead to reduced toxicity-related side effects and increased tumor-specific immune activity.3. Further development of TIS in cancer treatment could be facilitated by identifying additional compounds and targeted approaches for senescence induction.